ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 1826 • 2014 ACR/ARHP Annual Meeting

    A Renal Activity Index May Predict Histological Activity in Lupus Nephritis in Children

    Khalid Abulaban1, Michael Bennett2, Marisa Klein-Gitelman3, Stacy P. Ardoin4, Kelly A. Rouster-Stevens5, Lori B. Tucker6, Kasha Wiley7, Shannen Nelson8, Karen Onel9, Nora G. Singer10, Kathleen M. O'Neil11, Elizabeth Brooks12, B Anne Eberhard13, Lawrence K. Jung14, Lisa F. Imundo15, Tracey Wright16, David Witte17, Jun Ying18, Prasad Devarajan2 and Hermine I. Brunner19, 1Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, 4Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, 5Pediatrics, Emory University School of Medicine, Atlanta, GA, 6Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 7Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, 8Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 10Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 11Division of Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, 12Rheumatology, Univ Hospitals of Cleveland, Cleveland, OH, 13Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, 14Pediatric Rheumatology, Children's National Medical Center, Washington, DC, 15Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, 16Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, 17Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, 18University of Cincinnati, Cincinnati, OH, 19Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose Lupus Nephritis (LN) occurs in up to 80% of childhood-onset Systemic Lupus Erythematosus (cSLE) and it has a worse prognosis than adults. The current…
  • Abstract Number: 963 • 2014 ACR/ARHP Annual Meeting

    Reduction in Proteinuria and Normalization of C4 Complement Levels Predict Response to Treatment of Lupus Nephritis with Low-Dose Pulse Cyclophosphamide and Abatacept

    Sarah Goglin1, David Wofsy2, Miriam G. Cisternas3 and Maria Dall'era1, 1Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3MGC Data Services, Carlsbad, CA

    Background/Purpose: The response to treatment of lupus nephritis is unpredictable. There is a need to identify clinical and biochemical characteristics that can predict treatment outcome…
  • Abstract Number: 2719 • 2013 ACR/ARHP Annual Meeting

    Urinary Angiostatin As Alternative To Biopsy In  lupus Nephritis Patients Among Egyptian

    Shereen Algergawy1, Osama Alshaar2 and Rania Zakaria3, 1rheumatology and rehabilitation, associate prof at benha university faculty of medicine rheumatology and rehabilitation department Egypt, cairo, Egypt, 2clinical pathology, benha university faculty of medicine, benha, Egypt, 3pathology, benha university faculty of medicine, benha, Egypt

    Background/Purpose: Lupus nephritis (LN) is one of the most frequent manifestations of SLE and can be present in 60% of SLE patients.  Kidney biopsy remains…
  • Abstract Number: 2547 • 2013 ACR/ARHP Annual Meeting

    Anti-Ribosomal P Antibody Has a Protective Role In The Development Of Chronic Kidney Disease In Patients With Lupus Nephritis

    Kyung-Eun Lee1, Dong-Jin Park1, Tae-Jong Kim2, Yong-Wook Park1 and Shin-Seok Lee2, 1Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, 2Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea

    Background/Purpose: Anti-ribosomal P antibody (anti-P) in patients with systemic lupus erythematosus (SLE) is associated with neuropsychiatric manifestation. Of interest, recent studies have suggested that anti-P…
  • Abstract Number: 1262 • 2013 ACR/ARHP Annual Meeting

    Comparison Of Remission Rates For Pediatric Membranous Plus Proliferative Lupus Nephritis Versus Isolated Proliferative Lupus Nephritis: An Analysis Of The Childhood Arthritis and Rheumatism Research Alliance Registry

    Alexis Boneparth1, Norman T. Ilowite1 and The CARRA Registry Investigators2, 1Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, 2Duke Clinical Research Institute, Durham, NC

    Background/Purpose: Lupus nephritis (LN) affects many patients with pediatric systemic lupus erythematosus (pSLE) and is a significant cause of disease morbidity. Inability to achieve remission…
  • Abstract Number: 1263 • 2013 ACR/ARHP Annual Meeting

    Childhood-Onset Systemic Lupus Erythematosus In Ontario:  Long Term Outcomes In a Population-Based Cohort With Universal Health Care Coverage

    Deborah M. Levy1, Nadia Gunraj2, Janet E. Pope3, J. Carter Thorne4, Wesley Fidler5, Peter B. Dent6, Johannes Roth7, Roberta A. Berard8, Murray Berall9, Astrid Guttmann10 and Earl D. Silverman11, 1Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 2Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 3Medicine/Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, ON, Canada, 4Southlake Regional Health Centre, Newmarket, ON, Canada, 5Rheumatology, St. Joseph's Hospital, Thunder Bay, ON, Canada, 6McMaster University, Hamilton, ON, Canada, 7University of Ottawa, Ottawa, ON, Canada, 8Children's Hospital of Western Ontario, London, ON, Canada, 9Nephrology, Humber River Regional Hospital, Toronto, ON, Canada, 10Pediatrics, Institute for Clinical Evaluative Sciences, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 11Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Little is known about the long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care; however, linking clinical data to administrative…
  • Abstract Number: 645 • 2013 ACR/ARHP Annual Meeting

    Transcript Profiling Of Blood and Kidney Biopsies From Chinese Patients With Lupus Nephritis Reveals Concordant Activation Of Type I IFN Signaling In The Blood and Kidney, Reduced B Cell Presence In The Blood, and Increased Macrophages In The Kidney

    Zheng Liu1, Chris, A. Morehouse1, Xinfang Huang2, Philip Brohawn1, Nan Shen2, Yihong Yao1 and Brandon W. Higgs1, 1Translational Sciences, MedImmune, LLC, Gaithersburg, MD, 2Dept of Rheumatology, Shanghai Ren Ji Hospital, Shanghai, China

    Background/Purpose:  Up-regulated expression of type I interferon-regulated genes has consistently been observed within the peripheral blood in a large proportion of patients with active systemic…
  • Abstract Number: 582 • 2013 ACR/ARHP Annual Meeting

    A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines

    Neelufar Mozaffarian1, Steve Lobosco2 and Adam Roughley2, 1AbbVie, North Chicago, IL, 2Adelphi Real World Ltd., Macclesfield, United Kingdom

    Background/Purpose: Current pharmacotherapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN) includes combinations of nonsteroidal anti–inflammatory drugs (NSAIDs), antimalarials (AMs), glucocorticoids (GCs), and cytotoxic…
  • Abstract Number: 589 • 2013 ACR/ARHP Annual Meeting

    A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis

    Neelufar Mozaffarian1, Steve Lobosco2 and Adam Roughley2, 1AbbVie, North Chicago, IL, 2Adelphi Real World Ltd., Macclesfield, United Kingdom

    Background/Purpose: Patient satisfaction with disease control is an important component of overall health and well-being. Current treatment options for systemic lupus erythematosus (SLE) ±lupus nephritis…
  • Abstract Number: 594 • 2013 ACR/ARHP Annual Meeting

    Renal Biopsy Findings In Lupus Patient With Insignificant Proteinuria : Relation To Disease Activity and Clinical Manifestations

    Abdel Azeim M. Al-Hefny1, Samah El-bakry2, Sameh A. Mobasher3, Ola H. Nada4 and Nouran Abaza5, 1Department of Internal Medicine and Rheumatology, Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Cairo, Egypt, 2Department of Internal Medicine and Rheumatology, Assistant professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 3Department of Internal Medicine and Rheumatology, Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 4Department of Pathology, Faculty of Medicine, Ain Shams University, Lecturer of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, 5Physical medicine, Rheumatology and Rehabilitation, Lecturer of Physical medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Background/Purpose: Lupus nephritis (LN) remains one of the most serious manifestations of systemic lupus erythematosus (SLE) and is associated with significant morbidity and mortality. Early…
  • Abstract Number: 600 • 2013 ACR/ARHP Annual Meeting

    Factors Associated With Long-Term Renal Function Deterioration In Lupus Nephritis Treated Initially With Combined Prednisolone and Mycophenolate Mofetil (MMF) Or Tacrolimus (Tac)

    Chi Chiu Mok1, Chi Hung To1, King Yee Ying2, Cheuk-Wan Yim3 and Woon Leung Ng4, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Department of Medicine, Princess Margaret Hospital, Hong Kong, Hong Kong, 3Dept of Medicine, United Christian Hospital, Hong Kong, Hong Kong, 4Medicine, United Christian Hospital, Hong Kong, Hong Kong

    Background/Purpose: To study the risk factors for renal function decline in patients with lupus nephritis treated initially with combined steroid and MMF or Tac.Methods: Data…
  • Abstract Number: 580 • 2013 ACR/ARHP Annual Meeting

    Lupus Nephritis Flares Precipitated By Switching From Mycophenolate Mofetil to Azathioprine in Pre-Pregnancy Planning

    Natasha Jordan and David D'Cruz, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that affects women of childbearing age. Lupus nephritis is a major cause of morbidity and…
  • Abstract Number: L18 • 2013 ACR/ARHP Annual Meeting

    Long-Term Evaluation of Bone Mineral Density Change in Women Receiving Depot Leuprolide Acetate during Cyclophosphamide Therapy for Severe Lupus Nephritis

    Nathan Meier1 and Mary Anne Dooley2, 1Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Cohort studies demonstrate that 11-83% of female patients receiving cyclophosphamide (CYC) for treatment of severe manifestations of SLE develop premature ovarian failure (POF), dependent…
  • Abstract Number: 2249 • 2012 ACR/ARHP Annual Meeting

    Comparison of Mycophenolate Mofetil and Intravenous Cyclophosphamide As Induction Therapy in Korean Patients with Lupus Nephritis

    Dong-Jin Park1, Kyung-Eun Lee1, Tae-Jong Kim1, Yong-Wook Park1 and Shin-Seok Lee2, 1Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, 2Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea

    Background/Purpose: Although intravenous cyclophosphamide (IVC) pulses are generally accepted as standard therapy for induction treatment of active proliferative lupus nephritis (LN), several clinical trials have…
  • Abstract Number: 306 • 2012 ACR/ARHP Annual Meeting

    Children with Probable SLE by ACR Criteria May Need More Aggressive Lupus Treatment Early in the Disease Course

    Anjali Patwardhan1, Igor Dvorchik2 and Charles H. Spencer3, 1Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 2Biostatistics Division, Nationwide Children's Hospital,, Columbus, OH, 3Rheumatology, Nationwide Childrens Hospital, Columbus, OH

    Background/Purpose: This research explores whether delay of the childhood-onset SLE (cSLE) diagnosis until 4/11 ACR criteria are met affects patient outcome negatively Methods: Institutional Review…
  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology